Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of HSA/IFN-alpha2b Fusion Protein in Healthy Volunteers
NCT02781753Phase 1Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Apr 2016
- Primary completion
- Aug 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of albinterferon alfa-2b in hepatitis B (HBV) (2 arms), sponsored by CanSino Biologics Inc. Primary endpoint: Number of participants with adverse events after single dose at 4 weeks. Started Apr 2016; status: completed.
02
Drugs
albinterferon alfa-2b
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT02781753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781753.